Skip Navigation LinksHome > Professional Development > eLearning > SANGUINATE - PEGylated Bovine Carboxyhemoglobin (SANGUINATE™)

SANGUINATE - PEGylated Bovine Carboxyhemoglobin (SANGUINATE™)

Please note: AABB reserves the right to make updates to this program

Live Program Date: Thursday, June 14, 2018 - On-Demand Available

Master Program Number: 18EL-339 (see program format numbers below under Registration)

Educational Track: Patient Blood Management
Topic:  Technical/Clinical
Intended Audience: Director, Hospitals, Hospital Blood Banks, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Perfusionists, Physicians, Research Scientist, Resident/Fellow, Scientists, Students (MD, MT, SBB) Technologists, Transfusion Safety Officer
Teaching Level: Intermediate to Advanced

Director/ Moderator: Mark T. Friedman, DO, Medical Director, Blood Bank and Transfusion Service, Director, Pathology Residency Program, Assistant Professor of Pathology, Mount Sinai Health System ,St. Luke's-Roosevelt Hospital / Beth Israel Medical Centers, Icahn School of Medicine at Mount Sinai, New York, NY 
Speaker: Waseem Anani, MD, Associate Medical Director, BloodCenter of Wisconsin, Part of Versiti, Milwaukee, Wisconsin

Learning Objectives

After participating in this educational activity, participants should be able to:

  • Discuss the historical perspectives of oxygen therapeutics.
  • Identify the differences between PEGylated caboxyhemoglobin bovine (SANGUINATETM), a newer oxygen therapeutic agent under development, vs. prior products tested, including the anti-vasoconstrictive properties of SANGUINATETM
  • Discuss the clinical trials involving SANGUINATETM, including its benefits in sickle cell disease.

Program Description

The road to development of a clinically-effective oxygen therapeutic agent, so called “artificial blood”, has been fraught with failure and disappointment over the years.  Yet, a new bovine-based, PEGylated carboxyhemoglobin agent (SANGUINATETM) has shown promise in high-level human trials, including patients in which compatible blood was not available or not an option and in sickle cell patients. In this session, the clinical trials involving SANGUINATETM will be discussed as well as the speaker’s experience with the use of this newer blood substitute.

Registration

   Program #
Single Viewer: On-Demand Register18EL-339-4031
Group Viewing: On-Demand Register18EL-339-8031